lebrikizumab

Details

Generic Name:
lebrikizumab
Project Status:
Active
Therapeutic Area:
atopic dermatitis
Manufacturer:
Eli Lilly Canada, Inc.
Call for patient/clinician input open:
Brand Name:
TBC
Project Line:
Reimbursement Review
Project Number:
SR0819-000
Call for patient/clinician input closed:
NOC Status at Filing:
Pre NOC
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
As per proposed indication; for the treatment of adult and adolescent patients 12 years of age and older with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. Lebrikizumab injection can be used with or without topical corticosteroids.
Submission Type:
Initial
Fee Schedule:
Schedule A
Indications:
​For the treatment of adult and adolescent patients 12 years of age and older with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. Lebrikizumab injection can be used with or without topical corticosteroids.
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.
Key Milestones2
Call for patient/clinician input open20-Sep-23
Call for patient/clinician input closed14-Nov-23
Clarification:

- Patient input submission received from the Canadian Skin Patient Alliance, Eczema Society of Canada and Eczéma Québec

Submission received01-Nov-23
Submission accepted16-Nov-23
Review initiated17-Nov-23
Draft CADTH review report(s) provided to sponsor for comment08-Feb-24
Deadline for sponsors comments20-Feb-24
CADTH review report(s) and responses to comments provided to sponsor14-Mar-24
Expert committee meeting (initial)27-Mar-24
Draft recommendation issued to sponsorApril 09, 2024
To
April 11, 2024
Draft recommendation posted for stakeholder feedback18-Apr-24
End of feedback period03-May-24